The approval has been granted for Vyndaqel and Vyndamax to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
The approval is based on two Phase III trials, which evaluated combinations of dapagliflozin and saxagliptin on a background of metformin over 24 weeks, in patients with inadequately-controlled
Based in San Diego of California, Pharmapace has expertise in offering biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Pharmapace will be
Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will
Trelegy Ellipta is a once-daily single inhaler triple therapy, which includes fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI). Fluticasone is an inhaled corticosteroid, while umeclidinium is a
Initially, research will focus on Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive brain stem tumor. As part of the research collaboration, Tmunity will work with
Dengvaxia is said to be the first FDA-approved vaccine to prevent dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people aged between
With over 250 employees, the San Diego research center will focus on leveraging specialized drug discovery technologies, as well as advancing discovery research in gastroenterology and neuroscience, said
This medicine is currently in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer tumors. The agreement
Fast Track designation is intended to facilitate development and expedite review of therapies designed to treat serious conditions and fill an unmet medical need. Studies have shown that
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.